Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This a prospective real-world navigation study using tumor DNA sequencing technology to
sequence genes of previously treated and refractory gastrointestinal tumors, which are
generally considered to be highly heterogeneous and complex, to screen potential molecular
targeted drugs for individualized treatment. This study may provide feasibility and response
information, which will be the basis for designing better randomized trials, which may change
the pattern of cancer treatment. If the hypothesis is finally proved, it will help doctors
and molecular biologists to choose the best drug (or combination of drugs) based on the
individual oncogenomics of each patient.
Phase:
N/A
Details
Lead Sponsor:
Peking University
Collaborator:
Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China